ArticleJournal of cancer research and clinical oncology2008
Clinical significance of osteopontin expression in cervical cancer.
Article in Journal of cancer research and clinical oncology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 54 citations in OpenAlex.
- Advances in Cervical Cancer Diagnostics Based on Immunosensors: Innovative Approaches and Tumor Biomarkers.Current topics in medicinal chemistry · 2026Review
- Is Osteopontin a Reliable Biomarker for Endometriosis?International journal of molecular sciences · 2024Article
- Article
- Eight Aging-Related Genes Prognostic Signature for Cervical Cancer.International journal of genomics · 2023Article
- Bioinformatics analysis and identification of genes and pathways involved in patients with Wilms tumor.Translational cancer research · 2022Article
- Biological and Clinicopathological Characteristics of OPN in Cervical Cancers.Frontiers in genetics · 2022Article
- Review
- SPP1 Regulates Radiotherapy Sensitivity of Gastric Adenocarcinoma via the Wnt/Beta-Catenin Pathway.Journal of oncology · 2021Article
- A Five-Genes-Based Prognostic Signature for Cervical Cancer Overall Survival Prediction.International journal of genomics · 2020Article
- The cancer-related transcription factor RUNX2 modulates expression and secretion of the matricellular protein osteopontin in osteosarcoma cells to promote adhesion to endothelial pulmonary cells and lung metastasis.Journal of cellular physiology · 2019Article
- Features of the cervicovaginal microenvironment drive cancer biomarker signatures in patients across cervical carcinogenesis.Scientific reports · 2019Article
- A New Approach for the Diagnosis of Systemic and Oral Diseases Based on Salivary Biomolecules.Disease markers · 2019Review
- Cinobufagin Suppresses The Characteristics Of Osteosarcoma Cancer Cells By Inhibiting The IL-6-OPN-STAT3 Pathway.Drug design, development and therapy · 2019Article
- Cancer stem cells (CSCs), cervical CSCs and targeted therapies.Oncotarget · 2017Review
- Systematic analysis to identify a key role of CDK1 in mediating gene interaction networks in cervical cancer development.Irish journal of medical science · 2016Article
- Osteopontin Fragments with Intact Thrombin-Sensitive Site Circulate in Cervical Cancer Patients.PloS one · 2016Article
- OPN -Revisited.Journal of clinical and diagnostic research : JCDR · 2015Review
- Aberrant expression of osteopontin and E-cadherin indicates radiation resistance and poor prognosis for patients with cervical carcinoma.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2015Article
- Article
- Expression profiling of cervical cancers in Indian women at different stages to identify gene signatures during progression of the disease.Cancer medicine · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeNew diagnostic markers, other than squamous cell carcinoma (SCC) antigen, are needed for the detection of cervical cancer. Osteopontin (OPN) is a candidate frequently associated with several human malignancies. The purpose of this study was to evaluate the clinical significance of OPN expression as a diagnostic and prognostic biomarker for cervical cancer.
methodsImmunohistochemical staining of tissue from 97 cervical cancer cases and 22 healthy subjects was performed in order to determine the source of elevated plasma OPN levels. In addition, plasma OPN levels of 81 patients with cervical cancer, 34 patients with carcinoma in situ (CIS) of the uterine cervix, and those of 283 healthy women were measured with a commercially available solid-phase sandwich enzyme-linked immunosorbent assay (ELISA). The correlation between OPN levels and clinical features were examined and compared to SCC antigen levels in the cervical cancer cases.
resultsImmunohistochemical staining revealed OPN immunoreactivity in 67.0% (65/97) of cervical cancer tissues, and the immunostaining score in the cervical cancer tissue sections was 2.06 (95% CI, 1.70-2.42). There was no significant difference in immunostaining scores based on age, tumor size, and tumor stage, but higher scores (3.0< score <or=6.0) were significantly correlated with overall survival (P = 0.002) and disease-free survival (P = 0.033). Plasma OPN levels in women with cervical cancer (mean 355.8 ng/ml) were significantly higher (P < 0.001) than those of women with CIS (mean: 185 ng/ml) and healthy controls (mean 100 ng/ml). Within the cervical cancer patients, OPN levels correlated with increasing tumor size (P = 0.008) and tumor stage (P < 0.001). The sensitivity and specificity of OPN in detecting cervical cancer was 50.6 and 95.0%, respectively (cutoff value 215.5 ng/ml). Using a combination of markers proved to bring more sensitive results than using one marker (sensitivity: 65.4%, specificity: 90.9%). High plasma OPN levels (>215.5 ng/ml) were also correlated with disease-free survival (P = 0.038).
conclusionsThese results suggest that plasma OPN levels are potentially useful as a diagnostic and prognostic biomarker for cervical cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.